<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Chiesi Group 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=50301></link><description><![CDATA[Chiesi Group 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 13 Jun 2026 03:14:35 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2026/03/12_1028147215_20260312081621_1270474872.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Chiesi Group Announces New Chair and Vice Chair]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1034920</link><description><![CDATA[PARMA, Italy--(Business Wire/Korea Newswire)--Chiesi today announced a planned leadership change in its Board of Directors: Maria Paola Chiesi has been appointed Chair of the Board, succeeding Alessandro Chiesi, who is completing his tenure after nearly three years in the role, and will now continue to serve as Vice Chair.  During his mandate, Alessandro Chiesi oversaw the Group through a p...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2026/05/31017998_20260521083433_9462377276.jpg]]></url></image><pubDate>Thu, 21 May 2026 08:35:10 +0900</pubDate></item><item><title><![CDATA[Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1033494</link><description><![CDATA[PARMA, Italy & FRAMINGHAM, Mass.--(Business Wire/Korea Newswire)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2026/04/31017998_20260430082606_8959448613.jpg]]></url></image><pubDate>Thu, 30 Apr 2026 08:55:58 +0900</pubDate></item><item><title><![CDATA[Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1030127</link><description><![CDATA[PARMA, Italy & HOLMES CHAPEL, England--(Business Wire/Korea Newswire)--Chiesi Group (“Chiesi”), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak...]]></description><pubDate>Thu, 12 Mar 2026 08:36:14 +0900</pubDate></item></channel></rss>